Altamira Therapeutics Ltd.
CYTO · NASDAQ
12/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | – | – | – | -$3 |
| Dep. & Amort. | – | – | – | $0 |
| Deferred Tax | – | – | – | $0 |
| Stock-Based Comp. | – | – | – | $0 |
| Change in WC | – | – | – | -$0 |
| Other Non-Cash | – | – | – | -$1 |
| Operating Cash Flow | – | – | – | -$4 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | – | – | – | $0 |
| Net Acquisitions | – | – | – | $0 |
| Inv. Purchases | – | – | – | $0 |
| Inv. Sales/Matur. | – | – | – | $0 |
| Other Inv. Act. | – | – | – | $0 |
| Investing Cash Flow | – | – | – | $0 |
| Financing Activities | – | – | – | – |
| Debt Repay. | – | – | – | $0 |
| Stock Issued | – | – | – | $6 |
| Stock Repurch. | – | – | – | $0 |
| Dividends Paid | – | – | – | $0 |
| Other Fin. Act. | – | – | – | $4 |
| Financing Cash Flow | – | – | – | $4 |
| Forex Effect | – | – | – | $0 |
| Net Chg. in Cash | – | – | – | $0 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | – | – | – | $0 |
| End Cash | – | – | – | $0 |
| Free Cash Flow | – | – | – | -$4 |